翰森制药(03692.HK) 公布,集团自主研发的创新药注射用HS-20108获中国国家药品监督管理局批准,拟开展用于晚期实体瘤(如小细胞肺癌及神经内分泌肿瘤等)的临床试验。
同时,集团一款抗体-药物偶联物(ADC)注射用HS-20122获中国国家药品监督管理局批准,拟开展用于晚期实体瘤(包括非小细胞肺癌、头颈部鳞状细胞癌或结直肠癌等)的临床试验。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-07 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.